314130 — Genome&Company Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual cashflow statement for Genome&Company, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-36,004	-56,950	-50,653	-26,850	-7,687
Depreciation
Amortisation
Non-Cash Items	5,659	5,632	9,645	5,806	-16,326
Unusual Items
Other Non-Cash Items
Changes in Working Capital	2,048	5,855	1,737	5,988	-1,002
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-25,705	-36,002	-30,998	-7,609	-18,387
Capital Expenditures	-3,380	-7,276	-19,043	-4,186	-498
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-56,430	894	3,613	15,737	-6,996
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-59,810	-6,382	-15,430	11,551	-7,494
Financing Cash Flow Items	57.7	35.6	0	-49.8	27,023
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	17,617	78,550	30,568	5,246	-22,173
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-67,898	36,167	-15,860	9,192	-49,950